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297* The use of NIV within a regional adult Cystic Fibrosis Centre
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Introduction: Studies show Non-Invasive Ventilation (NIV) in Cystic Fibrosis (CF)
has reduced respiratory failure and aided secretion clearance. Our aim was to
examine the use of NIV in CF patients over 12 months (Jan–Dec 2008).
Method: A retrospective observational study of adult CF inpatients treated with
NIV was performed. Indication for NIV treatment, tolerance, complications and
perceived beneﬁt were recorded.
Results: 20 patients were treated with NIV over 35 episodes, 9 male with a mean
age of 31 years (SD 9). Median predicted lung function on admission was 23%
(10−53%). 13 patients had 1 NIV episode; 7 patients had 2−6 episodes. NIV was
used to aid sputum clearance in 5 patients (12 episodes) (34%), control hypercapnic
symptoms in compensated type II respiratory failure in 10 patients (17 episodes)
(49%) and to reverse acidosis in acute type II respiratory failure in 5 patients (6
episodes) (17%).
NIV was tolerated well in 18 patients (33 episodes) (94%), with subjective beneﬁt
in all episodes. In patients with raised PaCO2, reduction of headache was reported
in 9 patients (17 episodes) (74%), and decreased work of breathing in 3 patients
(3 episodes) (13%). All 5 patients (12 episodes) started on NIV to aid sputum
clearance and 1 patient with acute respiratory failure reported increased sputum
clearance with NIV. 2 patients were unable to tolerate the mask and felt no subjective
beneﬁt. The most common complications reported by those patients who tolerated
NIV were; aerophagia 4 (22%), pressure sores 3 (17%), difﬁculty sleeping 2 (11%)
and dehydration 2 (11%).
Conclusion: NIV was used successfully to control symptoms of hypercapnic
respiratory failure and sputum retention and was generally well tolerated.
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The pattern of deposition of inhaled medications is non-uniform in people with
CF. Deposition follows tidal ventilation, so inhalation in sitting tends to under-dose
the apices. One theory is that inhalation while in alternate side lying (ASL) would
improve homogeneity of deposition by preferentially dosing each lung (including
the apex) when it is dependent. Before testing this theory, we sought to determine
whether there was any slowing of delivery time with the ASL strategy.
Method: 24 adults (mean±SD age 30±9 y, 13F) with stable CF lung disease
(FEV1% pred 55±34) inhaled 4mL of normal saline via an LC Star® nebuliser
twice within 24 hours. During the ﬁrst inhalation, participants were randomised to
sit upright throughout the nebulisation period (SIT) or to alternate between left and
right side lying at each minute during the nebulisation period (ASL). Participants
used the opposite positioning regimen during their second inhalation. The nebuliser
was stopped and weighed each minute to determine output until the residual volume
(0.5mL) was reached.
Results: The delivery time did not signiﬁcantly differ between SIT
(18.54±3.80min) and ASL (17.96±3.53min), a difference of 0.58 min (95%CI
1.40 to −0.24). There was no signiﬁcant correlation between delivery time and
FEV1, FVC or height. In ASL, increasing the time between turns to 2min did not
signiﬁcantly affect the dose delivered on each side, however turning each 3min
resulted in less uniformity (mean ratio 1.32, 95%CI 1.24 to 1.40).
Discussion: ASL during inhalation therapy does not prolong delivery time. We are
now investigating the effect of ASL on uniformity of deposition with radioaerosol
scans.
Supported by: NHMRC CCRE in Respiratory & Sleep Medicine.
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This 4 month randomised cross-over trial compared taking Pulmozyme at 4pm,
with taking it immediately following the evening session of chest physiotherapy.
The primary outcome was FEF25 with secondary outcomes being FEV1 and
subjective feedback to assess whether there were any side effects from taking
Pulmozyme late at night.
A large number of subjects could not be recruited or had to be withdrawn from
the study due to increased respiratory symptoms. The total number of patients who
completed the study was 5, with a mean age of 11 years old. The results of this study
did not show any signiﬁcant differences between the two timing of Pulmozyme with
p = 0.557 for FEF25 and p = 0.868 for FEV1. Therefore no conclusions as to which
of the two different timings of Pulmozyme is the most effective at reducing airﬂow
obstruction can be drawn from this study.
There were no reported increase in overnight symptoms from any subjects from
taking Pulmozyme in the evening, so it could be concluded that Pulmozyme is safe
to administer at that time.
There have been several short term studies investigating this research question.
This study attempted to carry out a longer term study with a similar study design
as previous shorter term research. However the difﬁculty in subject recruitment
and the high drop out rates reported here have previously also been reported by
investigators attempting a longer term study with this design. The authors conclude
that this type of study design is not appropriate for a longer term investigation to
answer this research question.
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All sputum samples were collected from patients and rheological measurements
undertaken within 24 hours. All measurements were taken at a temperature of 25oC,
using an Anton Paar Physica MCR 501 rheometer. All samples were equilibriated
in the rheometer for a period of 1 hour before measurements were taken.
The intention was to freeze samples when supplied, but data illustrating the complex
viscosity of three examples of the mucus, on which measurements were taken
immediately, followed by freezing for a period of 4 days, showed that freezing
of the mucus can result in signiﬁcant changes of the gel structure. One example,
ETO801763 showed little change in the values of the complex viscosity but another
example, ETO801764, showed a considerable decrease, whilst a third example,
ETO801765, gave increased values.
Data illustrating the complex viscosity of a large number of samples will be
presented. Large variations in the values of the complex viscosity were observed,
ranging from almost 106 mPas to 3000mPas. Although the overall general pattern
of behaviour of the samples is a reduction in the value with increasing frequency
of oscillation, there were exceptions to this pattern, where an increase is initially
seen in some cases at low levels of oscillation but, in others, a sharp increase is
observed at very high levels.
In conclusion, consideration should be paid to the danger of complicating effects
of cryo-preservation prior to physical analysis of cystic ﬁbrosis sputum. This data
also suggests that components within the sputum generate unpredictable and highly
variable rheological data in different patients. Unravelling the biochemical basis of
this variability may assist the development of improved therapeutic approaches to
the treatment of cystic ﬁbrosis.
